B‑cell translocation 1 gene inhibits cellular metastasis‑associated behavior in breast cancer

Li,Wei; Zou,Shi‑Tao; Zhu,Ran; Wan,Jian‑Mei; Xu,Yan; Wu,Hao‑Rong

doi:10.3892/mmr.2014.2118

B‑cell translocation 1 gene inhibits cellular metastasis‑associated behavior in breast cancer

Authors:
- Wei Li
- Shi‑Tao Zou
- Ran Zhu
- Jian‑Mei Wan
- Yan Xu
- Hao‑Rong Wu
View Affiliations

Affiliations: Department of General Surgery, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Oncology Institute, Wuxi Fourth People's Hospital, Wuxi, Jiangsu 214062, P.R. China, School of Radiation Medicine and Protection, Medical College, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Advanced Health Center, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123, P.R. China
Published online on: April 4, 2014 https://doi.org/10.3892/mmr.2014.2118
Pages: 2374-2380

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

B‑cell translocation gene 1 (BTG1) is a member of the BTG/transducer of ERBB2 family, which regulates cell cycle progression in a variety of cell types and may have a role in inhibiting proliferation, promoting apoptosis and stimulating cellular differentiation in numerous cell types. However, the role of BTG1 in cancer metastasis is yet to be elucidated. In the present study, analysis of clinical specimens revealed that BTG1 mRNA levels were lower in lymph node metastases than those in benign breast tumors and normal human breast tissue. The effect of BTG1 on the metastatic behavior of breast cancer cells following stable transfection with a BTG1 expression vector was also investigated. The overexpression of BTG1 was observed to inhibit cell adhesion, migration and invasion. Furthermore, the overexpression of BTG1 was found to be involved in the inhibition of the metastasis‑related proteins matrix metalloproteinase‑2 and ‑9, as well as the promotion of the cell‑cell adhesion‑associated protein E‑cadherin. In syngeneic nude mice breast tumor models, hepatic metastasis and angiogenesis were observed in the mice injected with the control cells, but not in those injected with pcDNA3‑BTG1 cells. Immunohistochemistry revealed that overexpression of BTG1 decreased vascular endothelial growth factor expression in tumors. To the best of our knowledge, this is the first study to show that BTG1 overexpression decreases migration and invasion of breast cancer cells and thereby inhibits distant metastasis in mice breast tumor models.

View Figures

View References

1	Mehlen P and Puisieux A: Metastasis: a question of life or death. Nat Rev Cancer. 6:449–458. 2006. View Article : Google Scholar : PubMed/NCBI
2	O’Shaughnessy J: Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 10(Suppl 3): 20–29. 2005.
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
4	Chang EL and Lo S: Diagnosis and management of central nervous system metastases from breast cancer. Oncologist. 8:398–410. 2003. View Article : Google Scholar
5	Lassman AB and DeAngelis LM: Brain metastases. Neurol Clin. 21:1–23. 2003. View Article : Google Scholar
6	Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L, Garoccio M, Germain D, Samarut J and Magaud JP: BTG1, a member of a new family of antiproliferative genes. EMBO J. 11:1663–1670. 1992.PubMed/NCBI
7	Berthet C, Guéhenneux F, Revol V, Samarut C, Lukaszewicz A, Dehay C, Dumontet C, Magaud JP and Rouault JP: Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells. 7:29–39. 2002. View Article : Google Scholar : PubMed/NCBI
8	Matsuda S, Rouault J, Magaud J and Berthet C: In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett. 497:67–72. 2001. View Article : Google Scholar : PubMed/NCBI
9	Bakker WJ, Blázquez-Domingo M, Kolbus A, Besooyen J, Steinlein P, Beug H, Coffer PJ, Löwenberg B, von Lindern M and van Dijk TB: FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol. 164:175–184. 2004. View Article : Google Scholar : PubMed/NCBI
10	Hata K, Nishijima K and Mizuguchi J: Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement. Exp Cell Res. 313:2356–2366. 2007. View Article : Google Scholar : PubMed/NCBI
11	Corjay MH, Kearney MA, Munzer DA, Diamond SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab Invest. 78:847–858. 1998.PubMed/NCBI
12	Lee H, Cha S, Lee MS, Cho GJ, Choi WS and Suk K: Role of antiproliferative B cell translocation gene-1 as an apoptotic sensitizer in activation-induced cell death of brain microglia. J Immunol. 171:5802–5811. 2003. View Article : Google Scholar : PubMed/NCBI
13	Rodier A, Marchal-Victorion S, Rochard P, Casas F, Cassar-Malek I, Rouault JP, Magaud JP, Mason DY, Wrutniak C and Cabello G: BTG1: a triiodothyronine target involved in the myogenic influence of the hormone. Exp Cell Res. 249:337–348. 1999. View Article : Google Scholar : PubMed/NCBI
14	Cho JW, Kim JJ, Park SG, Lee DH, Lee SC, Kim HJ, Park BC and Cho S: Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia. Proteomics. 4:3456–3463. 2004. View Article : Google Scholar : PubMed/NCBI
15	Poste G and Fidler IJ: The pathogenesis of cancer metastasis. Nature. 283:139–146. 1980. View Article : Google Scholar : PubMed/NCBI
16	Leber MF and Efferth T: Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 34:881–895. 2009.PubMed/NCBI
17	Woodhouse EC, Chuaqui RF and Liotta LA: General mechanisms of metastasis. Cancer. 80(8 Suppl): 1529–1537. 1997. View Article : Google Scholar : PubMed/NCBI
18	Silletti S, Paku S and Raz A: Tumor cell motility and metastasis: Autocrine motility factor as an example of ecto/exoenzyme cytokines. Pathol Oncol Res. 3:230–254. 1997. View Article : Google Scholar : PubMed/NCBI
19	Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J and Yao Z: Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res. 7:832–840. 2009. View Article : Google Scholar : PubMed/NCBI
20	Liotta LA and Stracke ML: Tumor invasion and metastases: biochemical mechanisms. Cancer Treat Res. 40:223–238. 1988. View Article : Google Scholar : PubMed/NCBI
21	Trojanek J: Matrix metalloproteinases and their tissue inhibitors. Postepy Biochem. 58:353–362. 2012.(In Polish).
22	Bussemakers MJ, van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FM and Schalken JA: Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 52:2916–2922. 1992.PubMed/NCBI
23	Tanigawa N, Amaya H, Matsumura M and Shimomatsuya T: Association of tumour vasculature with tumour progression and overall survival of patients with non-early gastric carcinomas. Br J Cancer. 75:566–571. 1997. View Article : Google Scholar : PubMed/NCBI
24	Gasparini G: Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer. 32A:2485–2493. 1996. View Article : Google Scholar : PubMed/NCBI
25	Karaiossifidi H, Kouri E, Arvaniti H, Sfikas S and Vasilaros S: Tumor angiogenesis in node-negative breast cancer: relationship with relapse free survival. Anticancer Res. 16:4001–4002. 1996.PubMed/NCBI
26	Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR and Hellman S: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst. 88:1764–1769. 1996. View Article : Google Scholar : PubMed/NCBI
27	Silberman MA, Partin AW, Veltri RW and Epstein JI: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 79:772–779. 1997. View Article : Google Scholar : PubMed/NCBI
28	Obermair A, Kohlberger P, Bancher-Todesca D, Tempfer C, Sliutz G, Leodolter S, Reinthaller A, Kainz C, Breitenecker G and Gitsch G: Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol Oncol. 63:204–209. 1996. View Article : Google Scholar
29	Srivastava A, Laidler P, Davies RP, Horgan K and Hughes LE: The prognostic significance of tumor vascularity in intermediate-thickness (0.76–4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol. 133:419–423. 1988.
30	Denijn M and Ruiter DJ: The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects. Melanoma Res. 3:5–14. 1993. View Article : Google Scholar : PubMed/NCBI